Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Trigger

On 19 Nov 2025, Novelix Pharmaceuticals recorded a day change of -5.0%, underperforming the Sensex which posted a modest gain of 0.29%. The stock opened with a gap up of 5%, touching an intraday high of Rs 70.16, marking a new 52-week high. However, the momentum reversed sharply as the price declined to an intraday low of Rs 64, reflecting a drop of 4.22% from the opening level. This volatility within the trading session underscores the intense selling pressure that overwhelmed any buying interest.

Notably, the stock has fallen after five consecutive days of gains, indicating a potential trend reversal. Despite trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, the absence of buyers today has led to a lower circuit trigger, a rare and significant event that highlights the severity of the selling pressure.

Examining the broader performance metrics, Novelix Pharmaceuticals has demonstrated remarkable gains over multiple time horizons. The stock’s 1-year performance stands at 176.00%, vastly outpacing the Sensex’s 9.46% over the same period. Over three years, the stock has surged by 571.75%, compared to the Sensex’s 37.71%. Even on a 5-year and 10-year basis, the stock’s returns of 820.00% and 658.42% respectively, significantly exceed the Sensex benchmarks of 94.76% and 228.59%.

However, the year-to-date performance of Novelix Pharmaceuticals is flat at 0.00%, while the Sensex has gained 8.67%. This stagnation in the current calendar year, combined with the recent sharp decline and the presence of only sellers today, suggests a period of distress selling that contrasts with the company’s long-term growth trajectory.

The stock’s market cap grade is rated 4, and its Mojo Score stands at 50.0 with a current Mojo Grade of Hold, reflecting an adjustment in evaluation from a previous Sell grade as of 14 Nov 2025. The trigger for this revision, dated 19 Nov 2025, is identified as “only_sellers,” underscoring the exclusive presence of sell orders and the resultant lower circuit condition.

Such a scenario of exclusive selling interest and absence of buyers is often indicative of heightened risk perception among investors. It may reflect concerns over near-term fundamentals, sectoral pressures within retailing, or broader market dynamics affecting micro-cap stocks like Novelix Pharmaceuticals. The stock’s underperformance relative to its sector by -2.48% today further highlights the selective pressure it faces within its industry context.

Investors should note that despite the current distress signals, Novelix Pharmaceuticals remains above key moving averages, which historically have acted as support levels. The stock’s recent volatility and the lower circuit event may prompt a reassessment of risk appetite among market participants, especially given the stock’s micro-cap status within the retailing sector.

In summary, Novelix Pharmaceuticals is experiencing a pronounced selling wave with no buyers today, triggering a lower circuit and signalling distress selling. This development contrasts with the company’s strong multi-year performance but aligns with a short-term pause and correction after a sustained rally. Market participants are advised to monitor further price action and volume trends closely to gauge whether this selling pressure will persist or if a recovery phase will emerge.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →